The findings of a prospective study of patients with RA treated with IFX or etanercept (ETN), conducted by Cavazzana et al., showed comparable effectiveness measured by DAS between patients positive for anti-Ro/SS-A antibodies and negative for anti-Ro/SS-A antibodies. The gene discussed is RO60; the disease is rheumatoid arthritis.